RDA COVID-19 Guidelines and Recommendations: 2nd release

2nd Release Highlights

During the week since the first release, two cross-cutting COVID-19 sub-groups were set up focusing on Legal and Ethical aspects and Software. The seven sub-groups have kept up their relentless pace and the main updates in this version, with respect to the 1st release on the 24 April 2020, include:

• Section 3 -Foundational Principles/Recommendations - modifications
• Section 4 - Clinical - updated
• Section 6 - Epidemiology - revised
• Section 8 - Omics - revised
• Section 9 - Overarching Research Software Guidelines - new sub-section 9.3 initial guidelines for policy makers included
• Section 10 - Overarching Legal and Ethical Guidelines added

Furthermore, the editorial team have incorporated some of the feedback received via the Requests for Comments (RfC) process and sent directly to Co-chairs, Sub-group moderators and the Editorial team.

The social sciences and community participation sub-groups are working on updates and additions for future releases. You are invited to visit each of the sub-group pages (accessible from the COVID-19 Working Group landing page) to see specific ongoing activities and links to documents and resources.

Timing, Future Releases and weekly webinars

In terms of timing, weekly releases (every Friday) are foreseen between now and 22 May 2020. More information and insights on the plans for those releases, as well as highlights from the sub-groups are given during the weekly webinar every Tuesday at 11UTC – see Events page for details and to access previous recordings and presentations.

Request for Comments:

As always, RDA welcomes feedback on the content of the releases, the scope, the direction, is vital for all involved to shape and focus the document and the sections to be a useful and meaningful tool.

Call for Expertise

The Clinical Subgroup would greatly appreciate the help from clinical imaging data and immunological data experts. Please join the COVID-19 Clinical group or contact the RDA Secretariat at enquiries[at]rd-alliance.org

DRI is honoured to be be making direct contributions to this effort. Natalie Harrower is a Co-Chair of the RDA COVID-19 Working group, a member of the Editorial team, and a member of the Epidemiology sub-WG. Timea Biro is a moderator for the Community Participation group, which involves supporting each release from the group.